ACVRL1 and pulmonary arterial hypertension: In addition, heterozygous loss-of-function mutations in the type II BMP receptor BMPR2, as well as in ALK1, ENG, and BMP9, have been identified in patients with pulmonary arterial hypertension (PAH)18–21.